39
Participants
Start Date
March 1, 2025
Primary Completion Date
February 28, 2027
Study Completion Date
July 31, 2027
Device: Phase Ⅰ Dose Level 1
Patients in the first dose level will receive a cell dose of 1×10\^6 cells/kg.
Device: Phase Ⅰ Dose Level 2
Patients in the second dose level will receive a cell dose of 2×10\^6 cells/kg.
Device: Phase Ⅰ Dose Level 3
Patients in the third dose level will receive a cell dose of 4×10\^6 cells/kg. Based on these findings, the maximum tolerated dose (MTD) will be determined.
Device: Phase II MTD in Phase I
This group subjects received the MTD obtained in phase I.
Device: Phase II lower than the MTD in Phase I
This group subjects received a dose lower than the MTD
Wuhan Hamilton Biotechnology Co., Ltd
UNKNOWN
Tang Zhouping
OTHER